The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Sorafenib Tablets (200 -400 mg) twice daily
NLI
Shibīn al Kawm, Menoufia, Egypt
RECRUITINGVascular Endothelial Growth Factor A (VEGFA) genotyping
Genetic polymorphism of VEGFA
Time frame: At Baseline, 3 month, and 6 month after treatment.
Kinase insert domain receptor (KDR) genotyping
Genetic polymorphism of KDR
Time frame: At Baseline, 3 month, and 6 months after treatment.
Tumor markers
Determination of serum Alpha-Fetoprotein, AFP-L3
Time frame: At Baseline, 3 month, and 6 month after treatment.
Complete blood culture
Determination of hemoglobin concentration
Time frame: At Baseline 3 month, and 6 months after treatment.
Kidney function tests
Determination of Serum creatinine concentration
Time frame: At Baseline 3 month, and 6 months after treatment.
Liver function tests.
Determine serum level of ALT and AST
Time frame: At Baseline 3 month, and 6 months after treatment.
Safety outcome
Incidence of side effects such as (diarrhea, anorexia, nausea, vomiting, hand and foot syndrome)
Time frame: At Baseline, 3 month, and 6 months after treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.